Management of motor neurone disease
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Motor neurone disease is a progressive neurodegenerative disorder leading to severe disability and death. It is clinically characterised by mixed upper and lower motor neurone involvement affecting bulbar, limb, and respiratory musculature. Recent guidelines have established diagnostic criteria and defined management of the condition. In a proportion of familial amyotrophic lateral sclerosis there is a mutation in the gene encoding the enzyme copper/zinc superoxide dismutase 1; this has allowed mutation screening and generated considerable laboratory based research. The diagnosis must be given with care and consideration and close follow up is essential. Management involves a multidisciplinary team based in the hospital and the community. Riluzole is the only drug shown to have a disease modifying effect and has been approved by the National Institute for Clinical Excellence. The essence of care is good symptomatic management, including nutritional support with percutaneous endoscopic gastrostomy and ventilatory care with non-invasive ventilation. Palliative care should be introduced before the terminal stages after careful discussion with the patient and carers. Knowledge of this condition has grown dramatically recently with a parallel improvement in treatment and ability to deal with the most troublesome problems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lacomblez, L., Bensimon, G., Meininger, V, Leigh, P. N., & Guillet, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91680-3 · Cited by 1,301
Yang, Y., Hentati, A., Deng, H.-X., Dabbagh, O., Sasaki, T., Hirano, M., Hung, W.-Y., Ouahchi, K., Yan, J., Azim, A. C., et al. (2001) · Nature Genetics · doi:10.1038/ng1001-160 · Cited by 743
Predictive factors for early mortality after percutaneous endoscopic gastrostomy
Light, V. L., Slezak, F. A., Porter, J. A., Gerson, L. W., & McCord, G. (1995) · Gastrointestinal Endoscopy · doi:10.1016/s0016-5107(95)70132-x · Cited by 130
Communication Status and Survival with Ventilatory Support
Bach, J. R. (1993) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-199312000-00002 · Cited by 130
The psychological impact of MND on patients and carers
Goldstein, L. H., Adamson, M., Jeffrey, L., Down, K., Barby, T., Wilson, C., & Leigh, P. N. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00209-3 · Cited by 98
Cited by
The EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis:, Andersen, P. M., Abrahams, S., Borasio, G. D., de Carvalho, M., Chio, A., Van Damme, P., Hardiman, O., Kollewe, K., Morrison, K. E., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03501.x · Cited by 1,117
Percutaneous endoscopic gastrostomy: Indications, technique, complications and management
Rahnemai-Azar, A. A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i24.7739 · Cited by 578
Management guidelines for motor neurone disease patients on non-invasive ventilation at home
Eng, D. (2006) · Palliative Medicine · doi:10.1191/0269216306pm1113oa · Cited by 340
Andersen, P. M., Borasio, G. D., Dengler, R., Hardiman, O., Kollewe, K., Leigh, P. N., Pradat, P. ‐., Silani, V., & Tomik, B. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01351.x · Cited by 289
Kurt, A., Nijboer, F., Matuz, T., & K??bler, A. (2007) · CNS Drugs · doi:10.2165/00023210-200721040-00003 · Cited by 177
Metadata
- Authors
- Howard, R. S., & Orrell, R. W.
- Venue
- Postgraduate Medical Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-12-01
- Volume
- 78
- Issue
- 926
- Pages
- 736-741
- ISSN
- 0032-5473 (ISSN-L)
- 1469-0756
- OpenAlex
- W2168841100
- Cited by
- 88
- References
- 5
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.